Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
Roshan PK, Assistant Professor, Emergency Physician at Government Medical College, posted on LinkedIn:
”Breaking Down Pulmonary Embolism (PE) Treatment by Risk Level
From the 2022 NEJM Review on Pulmonary Embolism – a comprehensive guide by Kahn and de Wit:
Low-Risk PE (Stable, no RV strain or elevated biomarkers):
• Start with oral anticoagulants like apixaban (10mg 2x/day for 7 days, then 5mg 2x/day) or rivaroxaban.
• Outpatient treatment often safe if no other concerns.
• No thrombolysis or embolectomy needed.
• Duration: At least 3 months; longer if high recurrence risk.
Intermediate-Risk PE (Stable but with RV dysfunction or high biomarkers):
• Immediate low-molecular-weight heparin (LMWH) for anticoagulation.
• Hospital monitoring essential – watch for worsening.
• Thrombolysis only if deteriorating (systemic preferred; catheter-directed as alternative).
• Embolectomy if high bleeding risk or near-shock.
• Same duration as low-risk.
High-Risk PE (Unstable with hypotension/shock):
• IV unfractionated heparin + reperfusion therapy.
• Systemic thrombolysis first if no high bleeding risk.
• Surgical or catheter-directed embolectomy if thrombolysis contraindicated or fails.
• Urgent action to stabilize
Remember, risk stratification uses hemodynamics, imaging, and biomarkers. Always seek professional medical advice – this is for info only.”
Stay updated with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic